Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer ; volume:36 ; number:1 ; day:17 ; month:6 ; year:2024 ; pages:1-9 ; date:12.2024
Journal of the Egyptian National Cancer Institute / Egyptian National Cancer Institute; 36, Heft 1 (17.6.2024), 1-9, 12.2024
- Creator
-
Ezzeldin, Nada
El-Lebedy, Dalia
Hassan, Mirhane
Shalaby, Alaa Omar
Hussein, Sabah Ahmed Mohamed
Gharib, Ahmed Mohamed
Hamdy, Gehan
Mohammed, Asmaa Mahmoud
Ramadan, Abeer
Sobeih, Mohamed Emam
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43046-024-00219-1
- URN
-
urn:nbn:de:101:1-2407252119026.966168746083
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ezzeldin, Nada
- El-Lebedy, Dalia
- Hassan, Mirhane
- Shalaby, Alaa Omar
- Hussein, Sabah Ahmed Mohamed
- Gharib, Ahmed Mohamed
- Hamdy, Gehan
- Mohammed, Asmaa Mahmoud
- Ramadan, Abeer
- Sobeih, Mohamed Emam
- SpringerLink (Online service)
Other Objects (12)
Cell-free circulating tumor DNA in cancer
Quantifying circulating cell-free DNA in humans
Towards systematic nomenclature for cell-free DNA
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer
Cell-free DNA promotes malignant transformation in non-tumor cells
Quantitative characterization of tumor cell-free DNA shortening
Circulating cell-free DNA use for diagnosing cholangiocarcinoma
Cancer treatment monitoring using cell-free DNA fragmentomes
Circulating tumor cells (CTCs) and circulating cell-free tumor DNA (ctDNA) as blood-based biomarkers for managing non-small cell lung cancer (NSCLC) patients
An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release
Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia
Cell-free circulating tumor DNA in cancer
Quantifying circulating cell-free DNA in humans
Towards systematic nomenclature for cell-free DNA
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer
Cell-free DNA promotes malignant transformation in non-tumor cells
Quantitative characterization of tumor cell-free DNA shortening
Circulating cell-free DNA use for diagnosing cholangiocarcinoma
Cancer treatment monitoring using cell-free DNA fragmentomes
Circulating tumor cells (CTCs) and circulating cell-free tumor DNA (ctDNA) as blood-based biomarkers for managing non-small cell lung cancer (NSCLC) patients
An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release
Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia
Cell-free circulating tumor DNA in cancer
Quantifying circulating cell-free DNA in humans
Towards systematic nomenclature for cell-free DNA
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer
Cell-free DNA promotes malignant transformation in non-tumor cells
Quantitative characterization of tumor cell-free DNA shortening
Circulating cell-free DNA use for diagnosing cholangiocarcinoma
Cancer treatment monitoring using cell-free DNA fragmentomes
Circulating tumor cells (CTCs) and circulating cell-free tumor DNA (ctDNA) as blood-based biomarkers for managing non-small cell lung cancer (NSCLC) patients
An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release